CHRN is a weak-quality, momentum-failing name with no clear engine edge; the risk case dominates and the position is flagged for exit rather than accumulation.
Thesis pillars
- Quality Below Floor→Stable
- Momentum Gate Failure→Stable
- No Clear Engine Edge→Stable
- +1 more pillar — see the Why tab for full reasoning
ChronoScale Holdings Corporatio (CHRN) Stock Analysis
Range Bound setup
Technology · Information Technology Services
Sell if holding. Engine safety override at $20.24: Quality below floor (1.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10. Specifically: Below-average business quality; Rich valuation.
ChronoScale Corporation (formerly Ekso Bionics Holdings) designs and markets robotic exoskeleton products for physical rehabilitation and mobility, including EksoNR, Ekso Indego Therapy, and Ekso Indego Personal, sold to hospitals and rehabilitation facilities through its... Read more
Sell if holding. Engine safety override at $20.24: Quality below floor (1.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10. Specifically: Below-average business quality; Rich valuation. Chart setup: RSI 41 mid-range, Bollinger mid-band. Score 3.7/10, moderate confidence.
Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and 8k serious 2.05. Suitability: aggressive.
About ChronoScale Holdings Corporatio
About ChronoScale Corporation
Ekso Bionics Holdings' Enterprise Health exoskeletons — EksoNR, cleared by the FDA for spinal cord injury, brain injury, stroke, and multiple sclerosis rehabilitation, and Ekso Indego Therapy — generate the majority of company revenue from clinical settings, while its Personal Health division sells the Ekso Indego Personal device for home and community use. As of December 31, 2025, the company had signed reimbursement-channel partnerships with National Seating & Mobility, Bionic Prosthetics & Orthotics Group (serving 14 states), and Ottobock Patient Care, with over 50 individuals identified as qualifying for potential Medicare reimbursement.
The company earns revenue from device sales, EksoCare extended-warranty and service contracts, fee-for-service repairs, and training programs, with Personal Health sales dependent on a complex third-party reimbursement process spanning VA, Medicare, Medicaid, and private insurers that can involve lengthy delays between delivery and payment settlement. To reduce manufacturing costs, the company is transitioning a significant amount of its production to third-party manufacturers under agreements it has not structured as long-term supply contracts, and it separately distributes MediTouch Inc.'s BalanceTutor rehabilitation system under an exclusive U.S. distribution arrangement expected to launch in early 2026. The exoskeleton business itself, however, became secondary to a much larger corporate event: on February 15, 2026 the company signed a Contribution and Exchange Agreement to combine with Applied Digital Corporation's cloud computing subsidiary, Applied Digital Cloud, in a deal the 10-K said would leave APLD's contributing entity owning approximately 97% of the combined company.
Show full overview
That business combination closed on May 5, 2026, when Applied Digital Cloud became a wholly owned subsidiary and the company changed its name to ChronoScale Corporation, consistent with the roughly 97% equity stake the 10-K had flagged for APLD's Contributor entity. Less than a month later, on May 29, 2026, ChronoScale's board committed to divesting the entire Ekso Bionics exoskeleton business described throughout this filing, in order to focus solely on the cloud business acquired from APLD — meaning the medical-device operations this 10-K details are, as of the most recent 8-K, no longer the company's intended core business.
See also: Technology · Information Technology Services
From ChronoScale Corporation's most recent 10-K filing, extracted August 30, 2026.
Recent developments
updated 2026-09-04Recent Developments — ChronoScale Holdings Corporatio
Latest news
- NEWS ChronoScale Announces Plans With Microsoft For 50-MW AI Compute Deployment In North America — benzinga Aug 27, 2026 positive
- NEWS Nutanix Collaborates With ChronoScale To Jointly Offer Enterprise-Ready AI Infrastructure — benzinga Aug 18, 2026 positive
- NEWS 12 Information Technology Stocks Moving In Tuesday's Intraday Session — benzinga Jul 21, 2026 neutral
- NEWS AMC Entertainment, IREN, Hut 8 And Other Big Stocks Moving Higher On Monday — benzinga Jul 20, 2026 positive
- NEWS 10 Information Technology Stocks Moving In Thursday's Intraday Session — benzinga Jul 16, 2026 neutral
Generated 2026-09-05T01:07:04Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Material Events(8-K, last 90d)
- 2026-06-30Item 5.02LOWBoard increased from seven to eight members and appointed Andrew Cordell Schaap as director effective June 29, 2026, also seating him on the Audit and Related Party Transactions Committees. Company disclosed a subsidiary data center lease with a firm where Schaap is CEO, entered in the ordinary course of business.SEC filing →
- 2026-06-04Item 2.05MEDIUMBoard committed on May 29, 2026 to divest the Ekso Bionics subsidiary and focus operations solely on the cloud business, expected to complete in the first fiscal quarter. Company anticipates material severance, lease-termination, and other exit costs but could not yet estimate the total amount.SEC filing →
- 2026-05-20Item 5.02LOWAmended a November 5, 2025 disclosure of Phantom PSU awards (185,000 units to Davis, 40,000 to Wong, 32,000 to Jones) granted under the 2014 Equity Incentive Plan, vesting on change-in-control plus a stock price goal and settled in cash; Board revised administration terms on May 14, 2026.SEC filing →
- 2026-05-05Item 5.01HIGHBusiness combination with Applied Digital Corporation's cloud subsidiary closed May 5, 2026; Cloud became a wholly owned subsidiary, Contributor received newly issued shares giving it approximately 97% of the combined company, and the registrant changed its name to ChronoScale Corporation.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Unprofitable operations — net margin -70.3%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $20.24: Quality below floor (1.3 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.7/10. Specifically: Below-average business quality; Rich valuation. Chart setup: RSI 41 mid-range, Bollinger mid-band. Prior stop was $18.84. Score 3.7/10, moderate confidence.
Take-profit target: $24.50 (+20.9% upside). Prior stop was $18.84. Stop-loss: $18.84.
Quality below floor (1.3 < 4.0).
ChronoScale Holdings Corporatio trades at a P/E of N/A (forward N/A). TrendMatrix value score: 0.0/10. Verdict: Sell.
8 analysts cover CHRN with a consensus score of 4.0/5.
What does ChronoScale Holdings Corporatio do?ChronoScale Corporation (formerly Ekso Bionics Holdings) designs and markets robotic exoskeleton products for physical...
ChronoScale Corporation (formerly Ekso Bionics Holdings) designs and markets robotic exoskeleton products for physical rehabilitation and mobility, including EksoNR, Ekso Indego Therapy, and Ekso Indego Personal, sold to hospitals and rehabilitation facilities through its Enterprise Health market and to individual users via DME suppliers, the VA, and Medicare reimbursement in its Personal Health market. Devices are sold outright or financed through third-party subscription arrangements lasting 12 to 36 months. In May 2026 the company completed a business combination with Applied Digital Cloud